Published in Cancer on July 15, 2009
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des (2011) 1.05
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res (2010) 1.04
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia (2010) 1.03
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation. PLoS One (2010) 0.98
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics (2013) 0.94
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery. Oncotarget (2015) 0.94
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). PLoS One (2014) 0.92
Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway. Nucleic Acids Res (2011) 0.86
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer (2014) 0.83
A novel animal model for in vivo study of liver cancer metastasis. World J Gastroenterol (2012) 0.78
Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma. Mol Oncol (2011) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer (2003) 13.01
Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.96
Antibodies to plasminogen activator inhibit human tumor metastasis. Cell (1983) 2.82
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res (2008) 2.75
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol (2007) 2.11
Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol (2000) 2.09
Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst (2004) 1.82
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res (2003) 1.61
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res (2008) 1.40
Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis (2001) 1.36
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res (1994) 1.18
Urokinase receptor and colorectal cancer survival. Lancet (1994) 1.18
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer (2008) 1.12
The urokinase-system--role of cell proliferation and apoptosis. Histol Histopathol (2008) 1.08
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology (1994) 1.08
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer (2006) 1.07
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res (2002) 1.07
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg (2005) 1.06
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer (1997) 0.98
Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Ann Surg Oncol (2007) 0.97
Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer (2001) 0.91
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis (2007) 0.89
Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res (2006) 0.85
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol (2001) 0.83
Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. J Urol (2007) 0.83
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer (1995) 0.81
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Diversity arrays technology (DArT) for high-throughput profiling of the hexaploid wheat genome. Theor Appl Genet (2006) 3.43
A high-density consensus map of barley linking DArT markers to SSR, RFLP and STS loci and agricultural traits. BMC Genomics (2006) 3.18
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 2.93
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res (2008) 2.75
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene (2005) 2.24
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer (2007) 2.12
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg (2004) 1.99
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res (2004) 1.97
Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol (2005) 1.94
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst (2004) 1.82
The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res (2007) 1.80
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res (2002) 1.78
Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol (2008) 1.76
A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS One (2013) 1.74
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer (2005) 1.64
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer (2004) 1.62
A consensus genetic map of sorghum that integrates multiple component maps and high-throughput Diversity Array Technology (DArT) markers. BMC Plant Biol (2009) 1.62
Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res (2003) 1.61
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci U S A (2008) 1.58
Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res (2006) 1.58
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg (2003) 1.56
Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology (2005) 1.55
Differential angiogenic regulation of experimental colitis. Am J Pathol (2006) 1.55
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol (2006) 1.52
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 1.51
Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. PLoS One (2013) 1.51
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest (2007) 1.47
Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol (2003) 1.47
Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg (2002) 1.47
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol (2003) 1.45
G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood (2005) 1.45
Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol (2004) 1.45
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res (2002) 1.44
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.43
Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol (2004) 1.42